Boothbay Fund Management LLC Purchases Shares of 2,940 Quest Diagnostics Incorporated (NYSE:DGX)

Boothbay Fund Management LLC acquired a new position in shares of Quest Diagnostics Incorporated (NYSE:DGX - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 2,940 shares of the medical research company's stock, valued at approximately $444,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Coldstream Capital Management Inc. grew its stake in shares of Quest Diagnostics by 4.4% in the fourth quarter. Coldstream Capital Management Inc. now owns 18,788 shares of the medical research company's stock worth $2,834,000 after purchasing an additional 797 shares in the last quarter. Fuller & Thaler Asset Management Inc. lifted its holdings in Quest Diagnostics by 11.4% in the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 23,822 shares of the medical research company's stock valued at $3,594,000 after acquiring an additional 2,445 shares during the last quarter. MGO One Seven LLC acquired a new position in shares of Quest Diagnostics in the 4th quarter worth approximately $421,000. Price T Rowe Associates Inc. MD lifted its stake in Quest Diagnostics by 42.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,490,278 shares of the medical research company's stock valued at $828,265,000 after purchasing an additional 1,637,525 shares during the last quarter. Finally, Dark Forest Capital Management LP increased its holdings in shares of Quest Diagnostics by 54.0% in the fourth quarter. Dark Forest Capital Management LP now owns 2,493 shares of the medical research company's stock valued at $376,000 after buying an additional 874 shares in the last quarter. 88.06% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Quest Diagnostics news, SVP Karthik Kuppusamy sold 2,555 shares of Quest Diagnostics stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $170.00, for a total value of $434,350.00. Following the completion of the sale, the senior vice president now directly owns 10,575 shares in the company, valued at approximately $1,797,750. The trade was a 19.46 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Mark E. Delaney sold 403 shares of Quest Diagnostics stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $164.30, for a total transaction of $66,212.90. Following the completion of the sale, the senior vice president now directly owns 4,624 shares of the company's stock, valued at approximately $759,723.20. This trade represents a 8.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 55,903 shares of company stock worth $9,460,221 in the last ninety days. Company insiders own 8.16% of the company's stock.

Analyst Ratings Changes

A number of research firms recently commented on DGX. Piper Sandler raised their price objective on shares of Quest Diagnostics from $180.00 to $200.00 and gave the stock a "neutral" rating in a research note on Monday, April 28th. Leerink Partnrs raised Quest Diagnostics from a "hold" rating to a "strong-buy" rating in a research report on Monday, January 6th. JPMorgan Chase & Co. boosted their price target on Quest Diagnostics from $173.00 to $180.00 and gave the company a "neutral" rating in a research note on Tuesday, February 4th. Truist Financial increased their price target on shares of Quest Diagnostics from $182.00 to $190.00 and gave the stock a "hold" rating in a research note on Wednesday, April 23rd. Finally, Leerink Partners raised shares of Quest Diagnostics from a "market perform" rating to an "outperform" rating and increased their target price for the stock from $169.00 to $174.00 in a research report on Monday, January 6th. Eight research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $185.07.

Quest Diagnostics Price Performance

Shares of DGX stock traded down $0.43 during trading on Monday, hitting $177.52. The company had a trading volume of 834,646 shares, compared to its average volume of 964,530. The stock's 50-day moving average price is $169.42 and its 200 day moving average price is $162.17. Quest Diagnostics Incorporated has a one year low of $135.35 and a one year high of $179.32. The company has a debt-to-equity ratio of 0.82, a quick ratio of 1.02 and a current ratio of 1.10. The firm has a market capitalization of $19.82 billion, a P/E ratio of 23.08, a price-to-earnings-growth ratio of 2.16 and a beta of 0.52.

Quest Diagnostics (NYSE:DGX - Get Free Report) last announced its quarterly earnings data on Tuesday, April 22nd. The medical research company reported $2.21 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.15 by $0.06. Quest Diagnostics had a net margin of 8.80% and a return on equity of 15.07%. The business had revenue of $2.65 billion for the quarter, compared to analysts' expectations of $2.63 billion. Equities analysts expect that Quest Diagnostics Incorporated will post 9.7 EPS for the current fiscal year.

About Quest Diagnostics

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.